Share Price | Amneal Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Amneal Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Bollinger Bands also indicate a bullish stance on both weekly and monthly time frames. However, the weekly RSI is bearish, suggesting some short-term weakness, while the monthly RSI shows no signal. The daily moving averages are bullish, reinforcing the overall positive outlook. Dow Theory indicates a mildly bullish trend on the monthly chart, with no trend on the weekly. Additionally, the KST is bullish weekly but mildly bearish monthly, and the OBV shows a mildly bullish stance monthly.In terms of performance, Amneal has outperformed the S&P 500 across all multi-period returns, notably with a 375.23% return over three years compared to the S&P 500's 82.57%. Overall, the current technical stance is bullish, with strength indicated by multiple bullish signals, despite some mixed indicators in the short term.

Q: Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?

As of 1 March 2024, the valuation grade for Amneal Pharmaceuticals, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, particularly given its high P/E ratio of 51.39 compared to the industry average, which suggests that investors are paying a premium for its earnings. Additionally, the EV to EBITDA ratio stands at 8.71, further supporting the notion of overvaluation.In comparison to peers, Amneal's valuation metrics are concerning; for instance, its P/E ratio is significantly higher than industry norms, which could deter potential investors. The company’s stock has shown a YTD return of 23.86%, outperforming the S&P 500's 12.22%, but its one-week return of -2.78% contrasts sharply with the S&P 500's positive performance, highlighting recent volatility. Overall, the combination of high valuation ratios and recent performance trends suggests that Amneal Pharmaceuticals may not be a favorable investment at this time.

Q: What does Amneal Pharmaceuticals, Inc. do?

Overview: Amneal Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.Financial Snapshot: Market cap: Small CapKey Metrics: Industry: Pharmaceuticals & Biotechnology Dividend Yield: 0.00% Debt Equity: -999,999.00 Return on Equity: -999,999.00% Price to Book: 0.00 Contact Details: Details: No Company Details Available Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

773.62 k

Shareholding (Mar 2026)

FII

5.29%

Held by 120 FIIs

DII

90.24%

Held by 41 DIIs

Promoter

4.47%

Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Amneal Pharmaceuticals shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI, and has significantly outperformed the S&P 500 over three years.

View full answer

Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 51.39, overvaluation compared to industry peers, and recent stock volatility despite a year-to-date return of 23.86%.

View full answer

What does Amneal Pharmaceuticals, Inc. do?

22-Jun-2025

Amneal Pharmaceuticals, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry. It currently has no dividend yield, and its financial metrics indicate significant negative values for debt equity and return on equity.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 8.66% and Operating profit at 20.61% over the last 5 years
The company has a negative book value of Rs 70.79 crore

With a growth in Net Profit of 410.5%, the company declared Outstanding results in Mar 26

Risky -

High Institutional Holdings at 59.47%

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,728 Million (Small Cap)

P/E

22.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-32.15

Return on Equity

-999,999.00%

Price to Book

-52.66

Revenue and Profits:

Net Sales:

723 Million

(Quarterly Results - Mar 2026)

Net Profit:

78 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.87%

6 Months

22.72%

1 Year

93.04%

2 Years

117.63%

3 Years

502.05%

4 Years

356.21%

5 Years

149.83%

Amneal Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.66%

EBIT Growth (5y)

20.61%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.47%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-52.66

EV to EBIT

15.05

EV to EBITDA

9.65

EV to Capital Employed

2.72

EV to Sales

1.99

PEG Ratio

0.05

Dividend Yield

ROCE (Latest)

18.09%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 59 Schemes (20.87%)

Foreign Institutions

Held by 120 Foreign Institutions (5.29%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 3.90% vs 5.49% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 217.07% vs 130.11% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "722.50",
          "val2": "695.40",
          "chgp": "3.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "186.10",
          "val2": "157.70",
          "chgp": "18.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "53.40",
          "val2": "56.90",
          "chgp": "-6.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.50",
          "val2": "-2.30",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "78.00",
          "val2": "24.60",
          "chgp": "217.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "197.70%",
          "val2": "140.30%",
          "chgp": "5.74%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.05% vs 16.73% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 273.07% vs -51.75% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,018.80",
          "val2": "2,794.00",
          "chgp": "8.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "646.70",
          "val2": "589.50",
          "chgp": "9.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "241.10",
          "val2": "258.60",
          "chgp": "-6.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-65.60",
          "val2": "-104.00",
          "chgp": "36.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "127.90",
          "val2": "-73.90",
          "chgp": "273.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "140.20%",
          "val2": "126.40%",
          "chgp": "1.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

722.50

695.40

3.90%

Operating Profit (PBDIT) excl Other Income

186.10

157.70

18.01%

Interest

53.40

56.90

-6.15%

Exceptional Items

-11.50

-2.30

-400.00%

Consolidate Net Profit

78.00

24.60

217.07%

Operating Profit Margin (Excl OI)

197.70%

140.30%

5.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 3.90% vs 5.49% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 217.07% vs 130.11% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

3,018.80

2,794.00

8.05%

Operating Profit (PBDIT) excl Other Income

646.70

589.50

9.70%

Interest

241.10

258.60

-6.77%

Exceptional Items

-65.60

-104.00

36.92%

Consolidate Net Profit

127.90

-73.90

273.07%

Operating Profit Margin (Excl OI)

140.20%

126.40%

1.38%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 8.05% vs 16.73% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 273.07% vs -51.75% in Dec 2024

All Annual Results

Company CV

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available